# IVIG vs SCIG in CIDP

> **NCT05584631** · PHASE1 · RECRUITING · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 20 (estimated)

## Conditions studied

- CIDP
- Immunoglobulin Deficiency
- Chronic Inflammatory Demyelinating Polyneuropathy

## Interventions

- **DRUG:** Intravenous immune globulin G
- **DRUG:** Subcutaneous immune globulin G

## Key facts

- **NCT ID:** NCT05584631
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-11
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05584631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05584631, "IVIG vs SCIG in CIDP". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05584631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*